From disposable endoscopes to TAVR to robotic surgery, there’s a whole host of medtech advances widely available now that weren’t around much 10 years ago. “In terms of technological advances, I would put this past decade as one of the most important for medical technology. From connected devices and robotics, to advances in material sciences […]
Frequency Therapeutics launches hearing loss trial, gains the fast track at FDA
Frequency Therapeutics (NSDQ:FREQ) said today that it launched a Phase 2a study and won fast-track designation at the FDA for its regenerative hearing loss drug. The fast-track program aims to speed up the approval of therapies for unmet needs in serious conditions. Woburn, Mass.-based Frequency’s FX-322 candidate is designed to stimulate the regrowth of sensory hair cells […]
Frequency Therapeutics prices $84m IPO
Frequency Therapeutics said yesterday that it priced its initial public offering at roughly $84 million. The 6-million-share offering priced at $14 per share and includes a 30-day underwriters option on another 900,000 shares that’s worth $12.6 million, the Woburn, Mass.-based company said. Get the full story at our sister site, Drug Delivery Business News.
Frequency Therapeutics registers $100m IPO
Frequency Therapeutics has registered an initial public offering of common stock worth $100 million. Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units. The company applied to the Securities and Exchange Commission have its common stock listed on The Nasdaq Global Market […]
FDA lures Vyaire exec Desai for CTO | Personnel Moves, August 23, 2019
The FDA lured former Vyaire Medical executive Vid Desai to take over as permanent CTO, according to Politico. Desai replaces acting CTO Mohammed Sohail Chaudhry, who’s held the role on an interim basis since 2015. Ebb Therapeutics puts Röösli in the corner office Insomnia device maker Ebb Therapeutics said yesterday that it put Eduard Röösli […]
Frequency Therapeutics inks $625m deal with Astellas, adds $62m Series C
Frequency Therapeutics said today that it raised a $62.0 million Series C round for the hearing loss drug it’s developing and inked a development and overseas distribution deal with Astellas Pharma that’s worth $625 million. Woburn, Mass.-based Frequency drew a $42 million Series B early this year; including the financing announced today, a $32 million Series A and seed […]
Frequency Therapeutics raises $42m for hearing regeneration drug
Frequency Therapeutics said today that it closed a $42 million Series B round to support the clinical development of its hearing regeneration drug, FX-322. The company is slated to publish top-line data from an ongoing Phase I/II study of FX-322 in the first half of the year. Get the full story at our sister site, Drug […]
Frequency completes enrollment in safety trial for hearing loss drug
Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate. The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in the […]
Lessons learned: How Jeff Karp stays at the forefront of innovation
Serial entrepreneur Jeff Karp has a philosophy for his laboratory: find important problems and get solutions to people quickly. To learn about the exciting technologies emerging from Karp’s lab, join us at DeviceTalks Boston on Oct. 8-10. After Jeff finished his PhD in chemical and biomedical engineering at the University of Toronto, he knew he wanted […]
Frequency Therapeutics launches clinical trial for hearing loss drug
Frequency Therapeutics said today that the first patients have been treated in a Phase I/II clinical trial to assess its first-in-class drug candidate for hearing restoration. The 24-patient trial is slated to include people with stable sensorineural hearing loss. Participants will receive an injection of Frequency’s FX-322 or a placebo in one ear, with a follow-up visit […]
Biolase CEO Flynn steps down | Personnel Moves – April 13, 2018
Biolase (NSDQ:BIOL) said this week its CEO Harold Flynn has resigned from the company to pursue other interests, and that current CFO John Beaver will step in to act as interim CEO. The transition will be made immediately, the Irvine, Calif.-based company said. “I would like to thank Harold for the leadership and commitment he has […]
